ONCOLOGY

Best outcomes with highest exposure, good presurgical T-cell function.

Reductions in mortality driven by lung cancer in men, breast cancer in women.

The newly identified genetic signature can classify non-WNT/SHH medulloblastoma patients into favourable- and high-risk groups.

Updated phase II data for the novel immunotherapeutic (SL-701) show “preliminarily promising survival curve” with good tolerability

Moderate-quality evidence supports doubled prophylactic benefit.

57% intracranial clinical benefit in phase 2 trial.

Overall, the incidence of cancer was 1.5 times higher in children who had received at least one CT scan five years previously.

The new review process will streamline FDA evaluation of other oncology drugs.

A NICE appraisal committee determined that it would be “unethical” not to offer the treatment to patients in the UK

Recombinant nonpathogenic polio-rhinovirus chimera achieves 21% 3-yr survival in patients with recurrent glioblastoma.

The regulatory agency has advised of cases of significant rebound hypercalcaemia after discontinuation in patients with giant cell tumour of bone.

WCGI 2018 - New developments in Neuroendocrine cancer (NEC) and Bile Duct Cancer (BDC) in the last 12 Months

Cytokine release syndrome causes multiple brain effects.

Available studies were very few and of low quality.